Shield Therapeutics plc (AIM:STX)

Market Cap	58.86M
Revenue (ttm)	25.70M
Net Income (ttm)	-21.71M
Shares Out	1.04B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,026,763
Average Volume	3,627,564
Open	5.52
Previous Close	5.55
Day's Range	5.50 - 5.80
52-Week Range	2.10 - 5.87
Beta	1.23
RSI	85.38
Earnings Date	Sep 5, 2025

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 63
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: STX

Financial Performance

In 2024, Shield Therapeutics's revenue was $32.18 million, an increase of 145.93% compared to the previous year's $13.09 million. Losses were -$27.18 million, -18.36% less than in 2023.

Financial numbers in USD